OhioHealth Multiple Sclerosis Lecture – How to Know Your Therapy is Working
Dr. Jacqueline Nicholas, OhioHealth MS neurologist, speaks how disease modifying MS therapies can help prevent new attacks over time and…
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults…
Stuart Schlossman
AAN Issues New Guidelines on Disease-Modifying Therapies in MS, Including Switching, Stopping and Pregnancy
30th April 2018 The new guideline aims to help clinicians choose among as many as two dozen potential therapies which,…
Stuart Schlossman
#AAN2018 — Ocrevus Lowers Immune Response to Vaccines in Relapsing MS, Phase 3 Trial Shows
Treatment with Ocrevus (ocrelizumab) is linked to a reduced immune response to vaccinations in patients with relapsing multiple sclerosis (MS), according to a Phase…
Stuart Schlossman
Israeli Scientists May Have Found A Cure for MS, Alzheimer’s, Crohn’s And Colitis in One Single Drug
Click here or the above box to listen to this message :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: Click here to receive MS news and information…
Stuart Schlossman
#AAN2018 – Celgene to Present Latest Data on Ozanimod’s Safety and Effectiveness
Celgene’s oral treatment candidate ozanimod can effectively reduce relapse rates in multiple sclerosis (MS) patients with mild to moderate disability, results of…
Stuart Schlossman
NEW OCREVUS (OCRELIZUMAB) DATA AT AAN DEMONSTRATE SIGNIFICANT REDUCTIONS IN DISEASE ACTIVITY AND DISABILITY PROGRESSION IN RELAPSING MULTIPLE SCLEROSIS
April 23, 2018 · Four years of continuous treatment with OCREVUS showed a sustained reduction in underlying disease activity in relapsing…
Stuart Schlossman
Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug
April 11, 2018, 06:26:00 PM EDT By Zacks Equity Research, Zacks.com Shutterstock photo Mylan N.V. MYL announced that it has inked an agreement with…
Stuart Schlossman
This Multiple Sclerosis Treatment (CLADRIBINE) Just Got Approved in United Arab Emirates
According to a story from PR Newswire, the science and tech company Merck recently announced that Mavenclad (cladribine) was recently…
Stuart Schlossman
Frequently Asked Questions: Generic and Biosimilar – Medications
What is a generic medication? A generic medication is a product that is equivalent to a brand-name medication whose patent protections have…
Stuart Schlossman
